Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication.

Michaelis M, Paulus C, Löschmann N, Dauth S, Stange E, Doerr HW, Nevels M, Cinatl J Jr.

Cell Mol Life Sci. 2011 Mar;68(6):1079-90. doi: 10.1007/s00018-010-0510-8. Epub 2010 Aug 30.

PMID:
20803231
2.

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.

Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.

J Cell Physiol. 2009 Jul;220(1):214-21. doi: 10.1002/jcp.21753.

PMID:
19288493
3.

Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells.

Ou DL, Shen YC, Yu SL, Chen KF, Yeh PY, Fan HH, Feng WC, Wang CT, Lin LI, Hsu C, Cheng AL.

Cancer Res. 2010 Nov 15;70(22):9309-18. doi: 10.1158/0008-5472.CAN-10-1033. Epub 2010 Nov 9.

4.

PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.

Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM.

Anticancer Res. 2010 Dec;30(12):4951-8.

5.

Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.

Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL.

Clin Cancer Res. 2009 Sep 15;15(18):5820-8. doi: 10.1158/1078-0432.CCR-08-3294. Epub 2009 Sep 8.

6.

Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib.

Messmer D, Fecteau JF, O'Hayre M, Bharati IS, Handel TM, Kipps TJ.

Blood. 2011 Jan 20;117(3):882-9. doi: 10.1182/blood-2010-04-282400. Epub 2010 Nov 15.

7.
8.

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.

Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M.

Mol Cancer Ther. 2008 Oct;7(10):3129-40. doi: 10.1158/1535-7163.MCT-08-0013. Review.

9.

Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.

Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Wellik LE, Witzig TE, Rajkumar SV, Adjei AA, Kumar S.

Oncogene. 2010 Feb 25;29(8):1190-202. doi: 10.1038/onc.2009.403. Epub 2009 Nov 23.

10.

Targeting Raf-kinase: molecular rationales and translational issues.

Caraglia M, Tassone P, Marra M, Budillon A, Venuta S, Tagliaferri P.

Ann Oncol. 2006 Jun;17 Suppl 7:vii124-7. Review.

PMID:
16760274
11.

Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.

Ambrosini G, Cheema HS, Seelman S, Teed A, Sambol EB, Singer S, Schwartz GK.

Mol Cancer Ther. 2008 Apr;7(4):890-6. doi: 10.1158/1535-7163.MCT-07-0518.

12.

Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.

Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R.

J Clin Endocrinol Metab. 2011 Apr;96(4):997-1005. doi: 10.1210/jc.2010-1899. Epub 2011 Feb 2. Erratum in: J Clin Endocrinol Metab. 2011 Jul;96(7):2286. Busaidy, Naifa L [added]; El Naggar, Alder K [corrected to El Naggar, Adel K]. J Clin Endocrinol Metab. 2012 Apr;97(4):1399.

13.

Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.

Klein M, Schermuly RT, Ellinghaus P, Milting H, Riedl B, Nikolova S, Pullamsetti SS, Weissmann N, Dony E, Savai R, Ghofrani HA, Grimminger F, Busch AE, Schäfer S.

Circulation. 2008 Nov 11;118(20):2081-90. doi: 10.1161/CIRCULATIONAHA.108.779751. Epub 2008 Oct 27.

PMID:
18955668
14.

Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.

Lee MH, Lee SE, Kim DW, Ryu MJ, Kim SJ, Kim SJ, Kim YK, Park JH, Kweon GR, Kim JM, Lee JU, De Falco V, Jo YS, Shong M.

J Clin Endocrinol Metab. 2011 Jan;96(1):E19-30. doi: 10.1210/jc.2010-1071. Epub 2010 Oct 6.

PMID:
20926530
15.

Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.

Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, Desai AA, Singleton PA, Sammani S, Sam L, Liu Y, Husain AN, Lang RM, Ratain MJ, Lussier YA, Garcia JG.

Physiol Genomics. 2008 Apr 22;33(2):278-91. doi: 10.1152/physiolgenomics.00169.2007. Epub 2008 Feb 26.

16.

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.

Cancer Res. 2006 Dec 15;66(24):11851-8.

17.

Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.

Wei G, Wang M, Hyslop T, Wang Z, Carr BI.

Int J Cancer. 2010 Dec 15;127(12):2949-58. doi: 10.1002/ijc.25498.

18.

A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.

Cheng H, Kari G, Dicker AP, Rodeck U, Koch WJ, Force T.

Circ Res. 2011 Dec 9;109(12):1401-9. doi: 10.1161/CIRCRESAHA.111.255695. Epub 2011 Oct 13.

19.

The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.

Martin del Campo SE, Levine KM, Mundy-Bosse BL, Grignol VP, Fairchild ET, Campbell AR, Trikha P, Mace TA, Paul BK, Jaime-Ramirez AC, Markowitz J, Kondadasula SV, Guenterberg KD, McClory S, Karpa VI, Pan X, Olencki TE, Monk JP, Mortazavi A, Tridandapani S, Lesinski GB, Byrd JC, Caligiuri MA, Shah MH, Carson WE 3rd.

J Immunol. 2015 Sep 1;195(5):1995-2005. doi: 10.4049/jimmunol.1400084. Epub 2015 Aug 3.

20.

The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines.

Heim M, Scharifi M, Zisowsky J, Jaehde U, Voliotis D, Seeber S, Strumberg D.

Anticancer Drugs. 2005 Feb;16(2):129-36.

PMID:
15655409

Supplemental Content

Support Center